1. Home
  2. VRAX vs EVAX Comparison

VRAX vs EVAX Comparison

Compare VRAX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.41

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$5.39

Market Cap

42.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
EVAX
Founded
2013
2008
Country
United Kingdom
Denmark
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
42.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
VRAX
EVAX
Price
$0.41
$5.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$3.00
$12.33
AVG Volume (30 Days)
570.8K
116.5K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,986.00
$7,650,000.00
Revenue This Year
$217,274.83
$128.77
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.17
52 Week Low
$0.31
$1.20
52 Week High
$3.20
$12.15

Technical Indicators

Market Signals
Indicator
VRAX
EVAX
Relative Strength Index (RSI) 49.47 50.53
Support Level $0.33 $4.56
Resistance Level $0.44 $5.02
Average True Range (ATR) 0.04 0.43
MACD 0.01 -0.01
Stochastic Oscillator 50.33 47.22

Price Performance

Historical Comparison
VRAX
EVAX

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Share on Social Networks: